Physician profile
Anna Bui
NPI 1245052752
$3,704.99
in general payments reported to CMS, 2019-2025
44 companies · $3,522 in 2025
The $3,522 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $183 · 2025: $3,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.00 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $560.78 | 2025 | Talvey, Tecvayli, Darzalex |
| Abbvie INC. | $347.47 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $261.51 | 2024-2025 | Tagrisso, Calquence |
| Novartis Pharmaceuticals Corporation | $229.93 | 2025 | |
| Eisai INC. | $163.86 | 2024-2025 | |
| Daiichi Sankyo INC. | $126.66 | 2025 | Enhertu, Datroway |
| Kerecis Limited | $126.38 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Takeda Pharmaceuticals U.S.A., INC. | $109.60 | 2024-2025 | Fruzaqla, Iclusig, Ninlaro |
| Glaxosmithkline, LLC. | $108.91 | 2025 | Ojjaara, Blenrep, Zejula |
| Pharmacosmos Therapeutics INC. | $108.32 | 2025 | Monoferric |
| Gilead Sciences, INC. | $100.03 | 2025 | Trodelvy |
| Seagen INC. | $99.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $91.15 | 2025 | Darzalex, Talvey, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $79.39 | 2025 | |
| Sobi, INC | $79.29 | 2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.32 | 2025 | Keytruda, Keytruda Qlex |
| Tersera Therapeutics LLC | $71.71 | 2025 | Zoladex, Xermelo |
| Genentech USA, INC. | $66.98 | 2025 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Karyopharm Therapeutics INC. | $65.92 | 2025 | Xpovio |
| Astellas Pharma US INC | $65.22 | 2025 | Xtandi, Vyloy |
| Blueprint Medicines Corporation | $57.93 | 2025 | Ayvakit |
| Pfizer INC. | $56.70 | 2024 | |
| Dendreon Pharmaceuticals LLC | $54.91 | 2025 | Provenge |
| Lilly USA, LLC | $54.80 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Agios Pharmaceuticals, INC. | $47.68 | 2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $42.58 | 2025 | |
| Rigel Pharmaceuticals, INC. | $39.98 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Corcept Therapeutics | $39.86 | 2025 | Korlym |
| Celgene Corporation | $30.28 | 2025 | Opdivo |
| Taiho Oncology, INC. | $29.73 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.27 | 2025 | Opdivo, Opdualag |
| Syndax Pharmaceuticals, INC. | $27.26 | 2025 | |
| Jazz Pharmaceuticals INC. | $26.90 | 2025 | |
| Beone Medicines USA, INC. | $26.43 | 2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $24.98 | 2025 | Qinlock, Romvimza |
| Geron Corporation | $24.83 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $21.94 | 2025 | Gomekli |
| Adaptive Biotechnologies Corporation | $21.63 | 2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $20.79 | 2025 | Danziten |
| Servier Pharmaceuticals LLC | $20.53 | 2024 | |
| Exelixis INC. | $19.09 | 2025 | Cabometyx |
| Incyte Corporation | $16.90 | 2025 | Monjuvi |
| Stemline Therapeutics INC. | $15.83 | 2025 | Orserdu |
| Iovance Biotherapeutics, INC. | $14.74 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.